CRV431 75mg + Placebo (1 softgel) + CRV431 225mg + Placebo (3 softgels)

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 25/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

NASH - Nonalcoholic Steatohepatitis

Conditions

NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, NAFLD - Nonalcoholic Fatty Liver Disease

Trial Timeline

Jun 23, 2020 → Oct 30, 2021

NCT ID

NCT04480710

About CRV431 75mg + Placebo (1 softgel) + CRV431 225mg + Placebo (3 softgels)

CRV431 75mg + Placebo (1 softgel) + CRV431 225mg + Placebo (3 softgels) is a phase 2 stage product being developed by Hepion Pharmaceuticals for NASH - Nonalcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04480710. Target conditions include NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, NAFLD - Nonalcoholic Fatty Liver Disease.

What happened to similar drugs?

0 of 5 similar drugs in NASH - Nonalcoholic Steatohepatitis were approved

Approved (0) Terminated (1) Active (4)

🔄IVA337 + PlaceboInventivaPhase 3

🔄MGL-3196 + PlaceboMadrigal PharmaceuticalsPhase 3

🔄Resmetirom + PlaceboMadrigal PharmaceuticalsPhase 3

❌Elafibranor + PlaceboGenfitPhase 3

🔄Aramchol free acid + PlaceboGalmed PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04480710	Phase 2	Completed	Jun 23, 2020	Oct 30, 2021	NASH - Nonalcoholic Steatohepatitis

Competing Products

20 competing products in NASH - Nonalcoholic Steatohepatitis

See all competitors

Product	Company	Stage	Hype Score
VK2809 + Placebos	Viking Therapeutics	Phase 2	32
TERN-501 + TERN-101	Terns Pharmaceuticals	Phase 2	32
TERN-101	Terns Pharmaceuticals	Phase 2	32
TERN-201	Terns Pharmaceuticals	Phase 1	26
IVA337 + IVA337 + Placebo	Inventiva	Phase 2	29
IVA337 + Placebo + Empagliflozin	Inventiva	Phase 2	29
IVA337 + Placebo	Inventiva	Phase 3	41
AZD2693	AstraZeneca	Phase 1	29
AZD4076 + Placebo	AstraZeneca	Phase 1	29
LIK066 + Placebo	Novartis	Phase 2	35
Tropifexor (LJN452) + Cenicriviroc (CVC)	Novartis	Phase 2	35
Tropifexor + Licogliflozin	Novartis	Phase 2	27
LMB763 + Placebo	Novartis	Phase 2	27
Tropifexor (LJN452) + Placebo	Novartis	Phase 2	27
TRO19622 + Placebo	Roche	Phase 2	35
SEL + SIM	Gilead Sciences	Phase 2	35
Seladelpar + Placebos	Gilead Sciences	Phase 2	27
Placebo + SIM	Gilead Sciences	Phase 2	27
Cilofexor	Gilead Sciences	Phase 1	29
Firsocostat + Fenofibrate	Gilead Sciences	Phase 1	29